Headache
Patients with migraine report superior outcomes with ubrogepant compared to triptans
SAN DIEGO — Those with migraine who switched from an oral triptan to ubrogepant reported superior outcomes compared with patients who chose another triptan,, according to data presented at the American Headache Society Annual Scientific Meeting.
Serum vitamin levels key to proper assessment, management of pediatric chronic migraine
SAN DIEGO — Obtaining serum vitamin levels in children with migraine should be part of symptom management, particularly for older adolescents, according to a speaker at the American Headache Society Annual Scientific Meeting.
Nutrient intake lower on days with nausea or vomiting in episodic migraine
SAN DIEGO —Individuals with episodic migraine had lower nutrient intake on days with nausea or vomiting compared with days without nausea, according to a poster from the American Headache Society Annual Scientific Meeting.
AI-based models accurately predict, show promise for expansion in headache
SAN DIEGO — AI-based models are currently best utilized as a predictor of headache, but show promise for expansion into the health care continuum, according to a speaker at the American Headache Society Annual Scientific Meeting.
Concurrent atogepant, ubrogepant safe, well-tolerated for migraine at 12 weeks
SAN DIEGO — Concurrent use of atogepant for preventive treatment of episodic migraine and ubrogepant for acute migraine treatment was safe and well-tolerated at 12 weeks, according to a study.
Evenamide meets primary endpoint in phase 2/3 study of patients with schizophrenia
Newron Pharmaceuticals announced positive topline results from its phase 2/3 study of evenamide for patients with chronic schizophrenia who have an inadequate response to current treatment with a second-generation antipsychotic.
Headache associated with attempted, completed suicide
DENVER — Among a large cohort of Danish citizens, headache disorders were strongly associated with attempted and completed suicide, according to a presenter at the American Academy of Neurology annual meeting.
‘Good friction:’ Experts share how artificial intelligence works in their office
DENVER — Incorporating artificial intelligence into daily practice can benefit both providers and patients, according to experts here at the American Academy of Neurology annual meeting.
Atogepant well-tolerated, linked to significant migraine reduction
Treatment with atogepant was safe, effective and well-tolerated over 12 weeks in those with episodic migraine who failed multiple conventional therapies, with significant reductions in mean monthly migraine days compared with placebo.
Sleep quality, energy, stress associated with incident headache onset
Poor sleep quality and low energy on the previous day were associated with incident morning headache, while higher than average energy levels and stress were linked to later-day headache onset, researchers reported in Neurology.